Rafael Amado - Research Ecosystem

The crosstalk between all parties in the process of discovery, development and commercialization of medicines has undergone significant evolution in the recent past. Not so long ago, it was incredibly rare to see competing pharmaceutical companies working together to develop combinations of medicines, even when there was compelling rationale.  Collaborations between industry and academia have been common but there have often been misalignments about objectives and incentives.  Relationships between the government and pharmaceutical companies have been mostly confined to regulatory interactions in the context of drug approvals. It’s exciting, then, to see that in just a few years, many of those dynamics are changing. Advances in scientific understanding of cancer biology, coupled with societal demands for higher therapeutic value have led to collaborations among industry to develop therapeutic combinations that work in synergy and circumvent resistance. Here are just a few examples.  Today GSK is working with Merck, Pfizer, Astra Zeneca and Amgen on the development of combination therapies in oncology. So far collaborations among industry have not reached sufficient maturity to result in commercialization, but it is likely that we will see those types of agreements in the coming years. With regards to academic-industry collaborations, last year we formed a consortium with six of the best cancer centers in the world, located at academic and global research institutions.  ...
Source: PHRMA - Category: Pharmaceuticals Authors: Source Type: news